Loading...
•
Jun 30, 2021
Allogene Q2 2021 Earnings Report
Allogene Therapeutics reported second quarter 2021 financial results.
Key Takeaways
Allogene Therapeutics reported a net loss of $70.9 million for the second quarter of 2021. The company ended the quarter with $913.2 million in cash, cash equivalents, and investments.
Phase 1 ALPHA data at ASCO 2021 showed a single dose of ALLO-501 was associated with overall response, complete response and durable response rates on par with autologous CD19 CAR T therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
Next CD19 Program Clinical Update Planned for Q4 2021.
ALLO-501A Pivotal Trial on Track for Initiation in Late 2021.
Ended Second Quarter with $913 Million in Cash, Cash Equivalents and Investments
Forward Guidance
Allogene continues to expect full year GAAP Operating Expenses to be between $300 million and $330 million including estimated non-cash stock-based compensation expense of $80 million to $90 million and excluding any impact from potential new business development activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...